Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Thomas Vorherr

Further Insights for Oral Uptake of Cyclic Peptides

Novartis Pharma AG

Gavin Bennett

Translating Macro cyclic and Constrained Peptide Therapeutics into the Clinic

Bicycle Therapeutics Ltd

08:00 - 08:50 50 mins
Registration
08:50 - 09:00 10 mins
Chairperson’s Opening Remarks
09:00 - 09:35 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Further Insights for Oral Uptake of Cyclic Peptides
  • Thomas Vorherr - Director Peptide Discovery , Novartis Pharma AG
more

In the context of permeability, latest insights on oral bioavailability of peptides are shared. In particular, strategies aiming at modifying peptides to maintain or to enhance solubility while enabling permeability constitute a significant challenge, but are of high interest to ensure a smooth drug discovery process. In this context, the role of metabolism is also discussed by comparing closely related peptides.

09:35 - 10:10 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Industry Case Study: Latest Developments in Oral Bioavailability of Peptide Products
more

If you are interested in giving this presentation please contact catherine.marshall@knect365.com

10:10 - 10:45 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Spotlight Presentation
  • A Representative from PolyPeptide - -, PolyPeptide
more
10:45 - 11:30 45 mins
Morning Coffee Break and Networking
11:30 - 12:05 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
R&D Strategies to Advance Oral Peptide Drug Delivery Products
  • Miriam Kidron - Chief Scientific Officer, Oramed Pharmaceuticals Inc.
more
12:05 - 12:40 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Design and Development of a Self-Assemble Drug Delivery System
  • Sheauyu Teddy Hsu, PhD - Managing Director, Adepthera
more

Therapeutic proteins and peptides are generally administered parenterally. Due to sensitivity to proteolysis and renal clearance, many peptide therapeutics need continuous administration or frequent doses of injections to achieve efficacy. Conjugation or fusion to polyethylene glycol (PEG), fatty acids, albumin, antibodies and unstructured proteins such as XTEN and PAS have been developed to extend the half-life of polypeptide drugs. These approaches extend the circulating half-life mainly by increasing the molecular mass of peptide moieties. Techniques employing slow-release carriers, including oil suspension, crystal particle suspension, liposomes, microspheres, and hydrogels have also been used to improve the pharmacokinetics, bioavailability, patient compliance, and efficacy of peptide therapeutics. However, most of these sustained-release techniques are associated with select disadvantages, including immunogenicity and complex fabrication processes. Therefore, alternative techniques that can further improve the delivery of peptide therapeutics are much needed. To improve the development of polypeptide therapeutics, we have developed a novel technology that generate self-assemble peptide therapeutic candidates with a minimum immunogenic footprint. In this presentation, we will discuss the discovery and design of this novel technology and its applications in peptide drug development.

12:40 - 13:15 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Spotlight Presentation
  • A Representative from Waters - -, Waters
more
13:15 - 14:30 75 mins
Lunch and Networking
14:30 - 15:05 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Lessons Learnt from Peptide Therapeutics in Preclinical and Clinical Development
  • Les Miranda - Director Research, Hybrid Modality Engineering, Therapeutic Discovery, Amgen
more
15:05 - 15:40 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Translating Macro cyclic and Constrained Peptide Therapeutics into the Clinic
  • Gavin Bennett - Head of Pre-Clinical Development, Bicycle Therapeutics Ltd
more
15:40 - 16:15 35 mins
Afternoon Coffee Break
16:15 - 16:50 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Lessons Learnt from Peptide Therapeutics in Preclinical and Clinical Development
more

If you are interested in giving this presentation please contact catherine.marshall@knect365.com

16:50 - 17:25 35 mins
PRECLINICAL, NON-CLINICAL & CLINICAL DEVELOPMENTS, DELIVERY & FORMULATION
Feedback from Rhythm Pharmaceuticals, Inc: Lessons Learnt from Peptide Therapeutics in Preclinical and Clinical Development
  • Lex Van der Ploeg - Chief Scientific Officer, Rhythm Pharmaceuticals
more
17:25 - 17:30 5 mins
End of Day 2 and Networking Evening Reception in the Exhibition Hall